Expert view: ddPCR whole cell DNA workflow efficiently measures success of CAR T-cell production
Not every step of CAR T-cell manufacturing can be tightly regulated, introducing some significant quality control challenges for companies developing CAR T cancer therapies
For example, when scientists transduce a population of T cells with the CAR gene using the virus, the transduction of the gene into the genome needs to be at a level that it does not have too many or too few events. Knowing the percent transduction efficiency of the cells helps ensure that the treatment is safe and effective.
